Quantcast

Quanterix Expands Headquarters to New, State-of-the-Art Facility in Billerica, Mass. as Demand Continues to Grow for its Disruptive Simoa Platforms

World-class facility will offer the Company nearly three times the
space for disruptive biomarker technology innovation and to accommodate
growing pharma services business

BILLERICA, Mass.–(BUSINESS WIRE)–Quanterix
Corporation
(NASDAQ:QTRX), a company digitizing biomarker analysis
with the goal of advancing the science of precision health, today
announced the relocation of its headquarters to a brand new,
state-of-the-art facility in Billerica, Mass. Brought on by Quanterix’
rapid growth, the move will allow the Company to unite its
CLIA-certified laboratory with its expanding workforce to accelerate
entry into pharmaceutical drug services and further increase its impact
on the transformation of precision healthcare.


“We experienced considerable success in our former facilities, launching
several new biomarker technologies that are beginning to disrupt drug
development and drug approval methodologies, acquiring Aushon to
accelerate our entry into Biopharma services and leading a successful
public offering in December 2017,” said Kevin Hrusovsky, Chairman and
CEO, Quanterix. “These advancements, coupled with the rapid adoption of
ultrasensitive protein biomarkers as critical tools for drug
development, next generation diagnostics discovery and early disease
detection health screens, have fueled our growth and heightened our
enthusiasm for the future. As we expand, we’re happy to keep our
headquarters in the greater Boston area, a center for medical innovation
and a compelling location for Quanterix to lead its global quest to
revolutionize healthcare utilizing digital biomarker innovations.”

The two story, 92,000 square-foot space features new offices and
expanded manufacturing and laboratory space. By bringing all business
operations together under the same roof as its CLIA-certified lab and
Accelerator Lab providing services to BioPharma, Quanterix is able to
offer customers a single home for all of its biomarker research needs
across a wide range of therapeutic categories. Additionally, the space
allows Quanterix to continue growing and innovating its technology bench
and industry-leading ultrasensitive assay menu, as the pharmaceutical
industry and medical community continue to put an emphasis on the
importance of biomarker testing.

“Massachusetts remains a global hub for innovation and research, and our
administration has prioritized efforts to create an environment that
supports this important sector of our economy,” said Massachusetts
Governor Charlie Baker. “Quanterix’ expansion is a great addition to the
Commonwealth’s digital health ecosystem and we look forward to the
opening of this new facility.”

Located at 900 Middlesex Turnpike in Billerica, Mass., the new
headquarters will help the company continue to attract top talent to
fuel its rapid growth and offers employees a world-class workplace
designed to support collaboration, innovation, and inspiration. The move
brings together employees from both its former Lexington and Billerica
sites into a single facility, and the additional space will enable
Quanterix to continue to grow its headcount, which increased by more
than 40 percent in 2018 alone.

“The new space gives us the room and amenities to inspire our incredible
team as they work to advance innovation and disrupt medicine. We’re
excited to remain in Boston and have this “state of the art” workplace
that we can call home, one that emulates our unique company culture and
compelling mission of personalized precision health,” continued
Hrusovsky.

About Quanterix

Quanterix is a company that’s digitizing biomarker analysis with the
goal of advancing the science of precision health. The company’s digital
health solution, Simoa, has the potential to change the way in which
healthcare is provided today by giving researchers the ability to
closely examine the continuum from health to disease. Quanterix’
technology is designed to enable much earlier disease detection, better
prognoses and enhanced treatment methods to improve the quality of life
and longevity of the population for generations to come. The technology
is currently being used for research applications in several therapeutic
areas, including oncology, neurology, cardiology, inflammation and
infectious disease. The company was established in 2007 and is located
in Billerica, Massachusetts. For additional information, please visit https://www.quanterix.com.

Forward-Looking Statements

This press release contains forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995. Words
such as “may,” “will,” “expect,” “plan,” “anticipate,” “estimate,”
“intend” and similar expressions (as well as other words or expressions
referencing future events, conditions or circumstances) are intended to
identify forward-looking statements. Forward-looking statements in this
news release are based on Quanterix’ expectations and assumptions as of
the date of this press release. Each of these forward-looking statements
involves risks and uncertainties. Factors that may cause Quanterix’
actual results to differ from those expressed or implied in the
forward-looking statements in this press release are discussed
in Quanterix’ filings with the U.S. Securities and Exchange Commission,
including the “Risk Factors” sections contained therein. Except as
required by law, Quanterix assumes no obligation to update any
forward-looking statements contained herein to reflect any change in
expectations, even as new information becomes available.

Contacts

Lindsay Poole
PAN Communications
617-502-4300
[email protected]

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.